tbuckley/cabot-search huggingface dataset:
Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies
Authors: Brad Kahl, Andrew W Roberts, John F Seymour, Ranjana H. Advani, Daniel Oscar Persky, Jianning Yang, Yue Cui, Todd Busman, Andrew Krivoshik, Sari Enschede, Rod Humerickhouse
Journal: Blood (2010)
Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models
Authors: Liandong Ma, Baohui Zhao, Richard Walgren, Joshua A Clayton, Wayne D Blosser, Timothy P Burkholder, Michele C Smith
Journal: Blood (2010)
Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.
Authors: A.M. Carella, M. Spriano, M. T. Corsetti, P. Scalzulli, G. Beltrami, E. Lerma, N. Cascavilla, M. Carella, S. Nati, A. Congiu, P. Musto
Journal: Blood (2005)
David Oliver: Time for an honest patient’s charter?
Authors: David Oliver
Journal: BMJ (2016)

The parliamentary act that led to the NHS’s creation set out what the public could expect—a universal service based on need, free at the point of delivery.1 Since then, the government has repeatedly set out standards that the public should expect.

We had John Major’s “patient’s charter,”2 then NHS standards for four hours in emergency departments or two weeks for investigation of suspected cancer.3 The NHS constitution strengthened the founding principles.4 The government response to the Francis inquiry guaranteed fundamental standards of care.5 The Care Quality Commission explicitly inspects services …
Abstract LB-124: Tumor-educated platelets allow for multiclass liquid biopsy-based diagnosis of cancer
Authors: Myron Best, Nik Sol, Irsan Kooi, Jonas Nilsson, Bart Westerman, Bauke Ylstra, Josephine Dorsman, Egbert Smit, Henk Verheul, Jaap Reijneveld, Bakhos Tannous, Pieter Wesseling, Thomas Würdinger
Journal: Cancer Research (2015)

Abstract Background: Cancer diagnosis is frequently hampered by limited access to adequate tissue of the primary tumor or of metastatic lesions. To overcome such limitations, the use of blood-based liquid biopsies has been suggested. Blood represents a biosource of tumor-educated platelets (TEPs) that sequester biomolecules during tumor growth, thereby altering the platelet mRNA profile. Methods: Blood platelet samples of 175 patients with cancer covering five tumor types (40 non-small cell lung cancer, 39 glioblastoma, 37 colorectal cancer, 35 pancreatic cancer, and 24 breast cancer) and of 52 healthy donors were isolated from whole blood by differential centrifugation. Total RNA was isolated, subjected to SMARTer mRNA amplification and submitted for whole transcriptome mRNA sequencing on the Illumina platform. Healthy donors, pan-cancer, and individual cancer classes were distinguished by a self-learning support vector machine (SVM) algorithm, using transcripts with moderate to high expression. Results: The 227 blood platelet samples were successfully sequenced and demonstrated a good intersample correlation of the detected mRNAs. Based on mRNA profiles, all tumor samples were clearly distinguished from healthy individuals: the pan-cancer SVM-supported classification test reached a sensitivity of 97% and a specificity of 92% to distinguish cancer patients from healthy controls. Also, all patients without overt metastases were correctly predicted as cancer patients. Moreover, a multiclass cancer diagnostics TEP-test, to distinguish multiple tumor subclasses and healthy controls provided an overall accuracy of 70%, far exceeding random classification. In addition, we distinguished HER2-positive, and mutant KRAS and EGFR tumors from their wild-type counterparts. Also, patients with metastatic tumors in lung, brain, and liver were accurately diagnosed according to the tumor in the tissue of origin. Conclusion: Molecular interrogation of TEP-based liquid biopsies may leverage cancer diagnostics. TEPs provide a circulating biosource for pan-cancer, multiclass, and molecular cancer classification. Of interest, this tool might also allow for blood-based highly sensitive early-stage cancer screening. Citation Format: Myron Best, Nik Sol, Irsan Kooi, Jonas Nilsson, Bart Westerman, Bauke Ylstra, Josephine Dorsman, Egbert Smit, Henk Verheul, Jaap Reijneveld, Bakhos Tannous, Pieter Wesseling, Thomas Würdinger. Tumor-educated platelets allow for multiclass liquid biopsy-based diagnosis of cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-124. doi:10.1158/1538-7445.AM2015-LB-124
Correlation Between Outcome and Genetic Abnormalities Identified by High-Density Single Nucleotide Polymorphism Array Analysis In Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multi-Lineage Dysplasia Treated with Azacitidine
Authors: Thomas Cluzeau, Chimène Moreilhon, Nicolas Mounier, Jean-Michel Karsenti, Lionel Mannone, Henri Vinti, Laurence Legros, Antoine Thyss, Georges Garnier, Jean Gutnecht, Daniel Re, Patrick Auberger, Jill-Patrice Cassuto, S. Dominique Raynaud
Journal: Blood (2010)
Reconstitution of Regulatory T Cell Subpopulations After Allogeneic Hematopoietic Stem Cell Transplantation and Graft-Versus-Host-Disease
Authors: Alienor Xhaard, Helene Moins, Marc Busson, Maryvonnick Carmagnat, Marie Robin, Patricia Ribaud, Nathalie Dhedin, Sarah Abbes, Antoine Toubert, Gerard Socie, Regis Peffault de Latour
Journal: Blood (2012)
Expression of CD56 Is an Independent Prognostic Factor to Predict Relapse in Acute Myeloid Leukemia with t(8;21): Results of Japan Adult Leukemia Study Group (JALSG) AML97 Protocol.
Authors: Noriyoshi Iriyama, Yoshihiro Hatta, Jin Takeuchi, Yoshiaki Ogawa, Shigeki Ohtake, Toru Sakura, Kinuko Mitani, Fumihiro Ishida, Masatomo Takahashi, Tomoya Maeda, Tohru Izumi, Hisashi Sakamaki, Shuichi Miyawaki, Sumihisa Honda, Yasushi Miyazaki, Tomohiko Taki, Masafumi Taniwaki, Tomoki Naoe
Journal: Blood (2012)
Increased eIF4E Expression and Phosphorylation in Late Phase Chronic Myelogenous Leukemia Occurs in a Bcr-Abl-Dependent Manner, and Can Be Targeted by a Novel Mnk Kinase Inhibitor, CGP57380, To Overcome Imatinib-Resistance.
Authors: Min Zhang, James C. Moore, Je Ko, Wuxia Fu, Sharmila Prabhu, John P. Fruehauf, Tiong Ong
Journal: Blood (2006)
Late In-the-Bag Intraocular Lens Dislocation
Authors: Olav Kristianslund, Marianne Råen, Atle E. Østern, Liv Drolsum
Journal: Ophthalmology (2016)

To compare the efficacy and safety of 2 operation methods for late in-the-bag intraocular lens (IOL) dislocation.Prospective, randomized, parallel-group surgical trial.Patients referred to Oslo University Hospital (tertiary referral center).We randomly assigned 104 patients (104 eyes) either to IOL repositioning by scleral suturing (n = 54) or to IOL exchange with retropupillary fixation of an iris-claw IOL (n = 50). One surgeon performed all operations. Patients were evaluated comprehensively before surgery, and most patients (82%) attended an examination 6 months after surgery.Best-corrected visual acuity (BCVA) 6 months after surgery.The mean postoperative BCVA was 0.24±0.29 logarithm of the minimum angle of resolution (logMAR) units (range, -0.18 to 1.16 logMAR) in the repositioning group and 0.35±0.54 logMAR (range, -0.20 to 3.0 logMAR) in the exchange group (P = 0.23). A BCVA of 20/40 or better (Snellen) was reached by 61% and 62% of the patients, respectively (P = 0.99). The mean postoperative corneal cylinder was 1.2±1.0 and 1.2±0.8 diopters, respectively (P = 0.84), and the postoperative endothelial cell density changes were -3±10% (P = 0.07) and -10±14% (P = 0.001), respectively (group difference, P = 0.04). Repositioning had a longer mean surgical time than exchange (P < 0.001). There were 2 (4%) and 0 cases of perioperative fluid misdirection syndrome, respectively. Postoperative complications were intraocular pressure (IOP) increase (n = 12), cystoid macular edema (CME; n = 3), and nonarteritic anterior ischemic optic neuropathy (n = 1) in the repositioning group, and IOP increase (n = 9), pupillary block (n = 1), choroidal effusion (n = 2), CME (n = 4), and redislocation (n = 1) in the exchange group.We found satisfactory and not significantly different outcomes for BCVA 6 months after surgery in the 2 groups. Both operation methods seemed safe, with low frequencies of serious perioperative and postoperative complications. However, some of the observed differences in complications should be taken into consideration when selecting the most suitable method in clinical practice.
Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression
Authors: Martin Jädersten, Leonie Saft, Andrea Pellagatti, Gudrun Göhring, Cristina Fernández-Santamaria, James S Wainscoat, Jacqueline Boultwood, Anna Porwit, Brigitte Schlegelberger, Eva Hellström-Lindberg
Journal: Blood (2008)
Human Bone Marrow as a Source of Multifunctional CMV-Specific CD4+ T Cells for Adoptive Cell Therapy.
Authors: Il-Kang Na, Anne Letsch, Ines Noack, Sandra Bauer, Jens Geginat, Petra Reinke, Hans Dieter Volk, Eckhard Thiel, Carmen Scheibenbogen
Journal: Blood (2007)
Evidence for Efficacy and Safety of Lentiviral Mediated Gene Transfer in T Cells and CD34+ Cells from Wiskott-Aldrich Syndrome Patients.
Authors: Samantha Scaramuzza, Sara Trifari, Francesco Marangoni, Silvana Martino, Ayse Metin, Anne Galy, Luigi Naldini, Alessandro Aiuti, Anna Villa, Loic Dupré, Maria Grazia Roncarolo
Journal: Blood (2006)
Comparasion of Hyper-CVAD Chemotherapy with Autologous Stem Cell Transplantation In Patients with Peripheral T Cell Lymphomas: A Single Centre Report.
Authors: Yang Xu, Xiaojin Wu, Ying Wang, Guangsheng He, Aining Sun, Huiying Qiu, Xiaowen Tang, Chengcheng Fu, Yue Han, Zhengming Jin, Miao Miao, Wu Depei
Journal: Blood (2010)
Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients
Authors: Lotta Hansson, Marzia Palma, Lars Adamson, Harriet Ryblom, Barbro Näsman-Glaser, Ingrid Eriksson, Kia Heimersson, Giusy Gentilcore, Håkan Mellstedt, Anders Österborg
Journal: Blood (2014)
Haploidentical Stem Cell Transplantation: High Doses of Alloreactive-T Cell Depleted Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve Survival without Causing Severe Gvhd.
Authors: Denis-Claude Roy, Silvy Lachance, Thomas Kiss, Sandra Cohen, Lambert Busque, Douglas Fish, Guy Sauvageau, Maarten Egeler, Jean Roy
Journal: Blood (2009)
The Potential Role of Circulating IL-17 Levels During the Peri-Transplant Period as a Predictor for Early Leukemia Relapse After Allogeneic Stem Cell Transplantation.
Authors: Byung Sik Cho, Ji-Young Lim, Seung-Ah Yahng, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Nak-Gyun Chung, Dae-Chul Jeong, Seok Lee, Heeje Kim, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Chang-Ki Min
Journal: Blood (2010)
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes
Authors: Helena W. Rodbard, Anne L. Peters, April Slee, Anjun Cao, Shana B. Traina, Maria Alba
Journal: Diabetes Care (2016)

OBJECTIVE To assess the effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic parameters and measures of glucose variability assessed by a 9-point self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) profiles, and patient-reported outcomes as an add-on to insulin among participants with type 1 diabetes. RESEARCH DESIGN AND METHODS In this randomized, double-blind study, 351 participants received canagliflozin 100 or 300 mg or placebo for 18 weeks. Change from baseline in daily mean glucose and SD was measured using a 9-point SMBG profile. In a subset of 89 participants who underwent CGM, the change from baseline in mean glucose, measures of glycemic variability (SD, coefficient of variation, and mean amplitude of glycemic excursions), and time spent in glycemic ranges were assessed. Change in treatment satisfaction was evaluated using the Diabetes Treatment Satisfaction Questionnaire (n = 328). RESULTS At week 18, reductions in daily mean glucose and SD measured using the 9-point SMBG profile were seen with canagliflozin 100 and 300 mg versus placebo. Reductions in mean glucose (−1.2, −0.7, and 0.6 mmol/L) and measures of glycemic variability assessed by CGM, such as changes in glucose SD (−0.3, −0.7, and 0.1 mmol/L), were also seen with canagliflozin 100 and 300 mg versus placebo, respectively. Canagliflozin 100 and 300 mg were associated with increases in time spent within target (glucose &amp;gt;3.9 to ≤10.0 mmol/L) compared with placebo (11.6%, 10.1%, and −3.5%, respectively) and commensurate reductions in time spent above the target level (glucose &amp;gt;10.0 mmol/L; −12.7%,−7.6%, and 5.7%, respectively). Participants showed greater improvement in treatment satisfaction with canagliflozin versus placebo; reductions in insulin dose, SD of glucose, and body weight contributed to the relationship between canagliflozin and satisfaction change. CONCLUSIONS Canagliflozin improved indices of glycemic variability and was associated with improvement in treatment satisfaction versus placebo over 18 weeks among participants with type 1 diabetes. Although these data from this study demonstrate the potential benefits of canagliflozin in people with type 1 diabetes, canagliflozin is not approved for the treatment of type 1 diabetes and should not currently be used in people with type 1 diabetes.
Dyspnoea after home improvement work
Authors: Alessio Marra, Nicoletta Bottero, Giovanna Leoncini, Giovanni Murialdo
Journal: BMJ (2016)

A 73 year old white man presented to the emergency department after unintentional ingestion of paraffin, which he had used as a paint remover two hours earlier. The episode was followed by cough, and the patient reported self induced vomiting. On admission he was eupnoeic and his respiratory rate, oxygen saturation, blood pressure, heart rate, and skin temperature were normal. The patient was a moderate smoker (15 cigarettes/day), and his history was notable only for a minor stroke two years previously without persistent sensory motor impairment. Physical examination, laboratory tests, and chest radiography were normal. No mucosal lesion was evident on an urgent gastroscopy. He was given vaseline oil and oral antacids. After 18 hours he developed hyperpyrexia (39°C), acute dyspnoea with desaturation (peripheral oxygen saturation 91% while breathing ambient air), and productive cough with blood streaks. A pulmonary examination identified fine crackles at the right lung base. White blood cell count and C reactive protein levels were increased (23×109/L (reference values: 4.5-9.8×109/L) and 216 mg/L (reference value: <5 mg/L) respectively). Contrast enhanced computed tomography (CT) of the chest was performed (fig 1⇓).



Fig 1  Computed tomography scan of the lung





### 1. What does the CT scan show and what is the diagnosis?

#### Short answer

The CT scan shows left pleural effusion and bilateral pulmonary infiltrates with consolidations, mixed with areas of low density involving the right middle lobe and the lingual (fig 2⇓), suggestive of acute lipoid pneumonia. The diagnosis is paraffin ingestion related pneumonia.



Fig 2  CT scan shows bilateral lung consolidation (arrows) and left pleural effusion (*). Areas of low fat attenuation are visible in the context of infiltrates (arrowheads)



#### Discussion

Multiple areas of reduced tomographic density (Hounsfield Unit (HU) …
MHC Disparity, Dose of Irradiation and T Cells in the Graft Determine the Persistence of Residual Host DCs, Mostly Skin-Derived Langerhans Cells (LCs) That Are Targets of DLI-Mediated Alloresponse.
Authors: Nadira Durakovic, Karl B. Bezak, Ephraim J. Fuchs, Leo Luznik
Journal: Blood (2004)
Long-Term Efficacy and Safety of Deferasirox (Exjade®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).
Authors: Elliott Vichinsky, Thomas D. Coates, Alexis A. Thompson, Brigitta U. Mueller, Darlene Lagrone, Matthew M. Heeney
Journal: Blood (2007)
Multivariate Analysis of Factors Influencing Stomatitis in Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Yumiko Ohbayashi, Osamu Imataki, Hiroaki Ohnishi, Minoru Miyake, Akinori Iwasaki, Takaaki Ogawa, Akira Kitanaka, Yoshitsugu Kubota, Terukazu Tanaka, Toshihiko Ishida, Shunichiro Nagahata
Journal: Blood (2007)
Translating Artificial Intelligence Into Clinical Care
Authors: Andrew L. Beam, Isaac S. Kohane
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway
Authors: Xuemin He, Rui Cheng, Kyoungmin Park, Siribhinya Benyajati, Gennadiy Moiseyev, Chengyi Sun, Lorin E. Olson, Yanhui Yang, Bonnie K. Eby, Kai Lau, Jian-xing Ma
Journal: Kidney International (2016)

Pigment epithelium-derived factor (PEDF) expression is downregulated in the kidneys of diabetic rats, and delivery of PEDF suppressed renal fibrotic factors in these animals. PEDF has multiple functions including anti-angiogenic, anti-inflammatory and antifibrotic activities. Since the mechanism underlying its antifibrotic effect remains unclear, we studied this in several murine models of renal disease. Renal PEDF levels were significantly reduced in genetic models of type 1 and type 2 diabetes (Akita and db/db, respectively), negatively correlating with Wnt signaling activity in the kidneys. In unilateral ureteral obstruction, an acute renal injury model, there were significant decreases of renal PEDF levels. The kidneys of PEDF knockout mice with ureteral obstruction displayed exacerbated expression of fibrotic and inflammatory factors, oxidative stress, tubulointerstitial fibrosis, and tubule epithelial cell apoptosis, compared to the kidneys of wild-type mice with obstruction. PEDF knockout enhanced Wnt signaling activation induced by obstruction, while PEDF inhibited the Wnt pathway-mediated fibrosis in primary renal proximal tubule epithelial cells. Additionally, oxidative stress was aggravated in renal proximal tubule epithelial cells isolated from knockout mice and suppressed by PEDF treatment of renal proximal tubule epithelial cells. PEDF also reduced oxidation-induced apoptosis in renal proximal tubule epithelial cells. Thus, the renoprotective effects of PEDF are mediated, at least partially, by inhibition of the Wnt pathway. Hence, restoration of renal PEDF levels may have therapeutic potential for renal fibrosis.
Adenosine Deaminase 2 Deficiency As a Cause of Pure Red Cell Aplasia Mimicking Diamond Blackfan Anemia
Authors: Ghadir S. Sasa, M. Tarek Elghetany, Katie Bergstrom, Sarah Nicholas, Ryan Himes, Robert A. Krance, Michael Hershfield, Joris van Montfrans, Alison Bertuch
Journal: Blood (2015)
Philadelphia Chromosome (Ph)-Positive Leukemia Patients Who Fail ABL1 Tyrosine Kinase Inhibitors Without BCR-ABL1 Kinase Domain Point Mutations Demonstrate Sensitivity To PI3-K/AKT Inhibitors
Authors: Christopher A. Eide, Samantha L. Savage, Jade Bryant, Anupriya Agarwal, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Thomas O'Hare, Michael W. Deininger, Marc M. Loriaux, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker
Journal: Blood (2013)
ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL
Authors: Martin van den Bent, Michael Vogelbaum, Sara Erridge, Anne Nowak, Marc Sanson, Alba Ariela Brandes, Wolfgang Wick, Paul Clement, Francois Baurain, Warren Mason, Helen Wheeler, Olivier Chinot, Michael Weller, Vassilis Golfinopoulos, Ken Aldape, Hendrikus Dubbink, Pieter Wesseling, Thierry Gorlia, Brigitta Baumert, Johan Kros
Journal: Neuro-Oncology (2016)

The benefit of adding chemotherapy to radiotherapy (RT) in newly diagnosed anaplastic glioma without 1p/19q co-deletion is unknown. The CATNON trial investigated the impact of adjuvant and/or concurrent chemotherapy with temozolomide (TMZ) in these tumors. Eligible were patients with newly diagnosed WHO grade III glioma without 1p/19q co-deletion, ≥ 18 years, and WHO performance status (PS) 0–2. All patients received RT 59.4 Gy in 33 fractions, and in a 2 x 2 factorial design were randomized to i. RT alone; ii. RT with concurrent daily 75 mg/m2 TMZ; iii. RT followed with 12 cycles of 150–200 mg/m2 adjuvant TMZ day 1–5/4 weeks; or iv. RT with both concurrent and 12 cycles of adjuvant TMZ. Stratification factors included O6-methyl-guanine DNA methyltransferase (MGMT) promoter methylation and PS. Primary endpoint was overall survival (OS). 748 patients and 534 events were needed to detect a HR reduction of 0.775 for both concurrent and adjuvant TMZ. An interim analysis was foreseen after 219 events (41%), and required a p value of 0.0084 for rejecting the Null hypothesis of no OS difference. Between Dec 2007 and Aug 2015 748 patients were randomized. On Oct 6, 2015 the interim analysis was conducted based on 221 events (median follow-up: 27 months). The analysis showed a HR reduction for OS of 0.645 (95% CI 0.450, 0.926; p= 0.0014) after adjuvant TMZ (arms iii and iv). MGMT status could be determined in 74% of patients, and was found methylated in 42% of them. MGMT methylation was prognostic for OS (HR 0.54, 95% CI 0.38, 0.77; p= 0.001), but at this stage did not predict improved outcome to adjuvant TMZ. For progression free survival (PFS), the risk adjusted HR of adjuvant TMZ was 0.586 (95% CI 0.472, 0.727; p < 0.0001).
In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination
Authors: Ella Willenbacher, Wolfgang Willenbacher, Gunther Gastl, Irmgard Verdorfer, Brigitte Kircher
Journal: Blood (2014)
Pre-Transplant Hyperferritinemia Is Associated with Low Incidence of Chronic Gvhd, High Relapse Rate and Impaired Survival in Patients with Hematological Malignancies after Allogeneic HSCT
Authors: Hans Gustaf Hagglund, Fryderyk Lorenz, Mats Remberger, Bjorn Wahlin, Anders Wahlin
Journal: Blood (2008)
Novel Concept of Platelet Production From Megakaryocyte in Intact Bone Marrow: Proplatelet and Thick Protrusion.
Authors: Shugo Kowata, Sumio Isogai, Kazunori Murai, Shigeki Ito, Koujiro Tohyama, Jiro Hitomi, Yoji Ishida
Journal: Blood (2012)